Oncology

Treatment with Human Mesenchymal Stem Cells (Remestemcel-L) Is Effective in Pediatric Patients with Refractory Acute Graft Versus Host Disease – American Society for Blood and Marrow Transplantation Meeting, February 2015

Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients – Biology of Blood and Marrow Transplantation Journal, August 2013

Unrelated Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Steroid-Refractory Acute Graft-Versus-Host Disease: a Phase I/II Study – Japanese Society of Hematology, July 2013

Remestemcel-L,The First Cellular Therapy Product for the Treatment of Graft-Versus-Host Disease – Drugs of Today, 2012

Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture – New England Journal of Medicine, 13 December 2012

Transplantation of Ex-Vivo Culture-expanded Parental Haploidentical Mesenchymal Stem Cells to Promote Engraftment in Pediatric Recipients of Unrelated Donor Umbilical Cord Blood: Results of a Phase I–II Clinical Trial – Bone Marrow Transplantation, 2009

Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease – American Society for Blood and Marrow Transplantation, March 2009

Successful Phase II Trial Using Mesenchymal Stem Cells (MSC) in Combination with Steroids for the Primary Treatment of Acute Graft Versus Host Disease (aGVHD) – American Society of Hematology meeting, December 2006